Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jacob Degner"'
Autor:
Mohan Liu, Jacob Degner, Justin Wade Davis, Kenneth B Idler, Ahmed Nader, Nael M Mostafa, Jeffrey F Waring
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195325 (2018)
Anti-drug antibody formation occurs with most biological agents across disease states, but the mechanism by which they are formed is unknown. The formation of anti-drug antibodies to adalimumab (AAA) may decrease its therapeutic effects in some patie
Externí odkaz:
https://doaj.org/article/54e61afa36b242ac93a2c3be0dc93e35
Autor:
Cyril Ramathal, David Masica, Peter Ansell, Bridget Riley-Gillis, Jacob Degner, Thanh Bui, Priya Narayanan, Josue Samayoa, Xin Huang, Robert F. Coleman, Jeffrey F. Waring
Publikováno v:
Cancer Research. 83:5426-5426
Discovery and validation of biomarkers derived from multi-dimensional clinico-genomic datasets have become critical in precision medicine and oncology drug development. The integration of multi-dimensional genomic and imaging datasets from patients i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10dbb2081e7f81e1e0aac8c98ff89320
https://doi.org/10.1158/1538-7445.am2023-5426
https://doi.org/10.1158/1538-7445.am2023-5426
Autor:
Denise Beck, Insa Winzenborg, Mohan Liu, Jacob Degner, Nael M. Mostafa, Peter Noertersheuser, Mohamad Shebley
Publikováno v:
Clinical pharmacokinetics. 61(4)
Elagolix is an orally active, gonadotropin-releasing hormone receptor antagonist approved for the management of endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids. Elagolix population pharmacokinetics and fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02392bacae3824d6ecd2cd32bf018d1e
https://pubmed.ncbi.nlm.nih.gov/34878624
https://pubmed.ncbi.nlm.nih.gov/34878624